Improved dissolution and micromeritic properties of naproxen

from spherical agglomerates: preparation, in vitro and in vivo

characterization
Damineni Saritha1*, Penjuri Subhash Chandra Bose2, Poreddy Srikanth Reddy2,
Grandhi Madhuri3, Ravouru Nagaraju3
1
Department of Pharmaceutics, Sultan-ul-uloom College of Pharmacy, Hyderabad, India, 2Department of Pharmaceutics,
MNR College of Pharmacy, Sagareddy, India, 3Institute of Pharmaceutical Technology, Sri Padmavathi Mahila Visva Vidyalayam,
Tirupathi, India

Naproxen, an anti-inflammatory drug, exhibits poor aqueous solubility, which limits the pharmacological
effects. The present work was carried out to study the effect of agglomeration on micromeritic properties
and dissolution. Naproxen agglomerates were prepared by using a three solvents system composed of
acetone (good solvent), water (non-solvent) and dichloromethane (bridging liquid). Differential Scanning
Calorimetry (DSC) results showed no change in the drug after crystallization process. X-Ray Powder
Diffraction (XRPD) studies showed the sharp peaks are present in the diffractograms of spherical
agglomerates with minor reduction in height of the peaks. The residual solvents are largely below
the tolerated limits in the agglomerates. Scanning Electronic Microscopy (SEM) studies showed that
agglomerates were spherical in structure and formed by cluster of small crystals. The agglomerates
exhibited improved solubility, dissolution rate and micromeritic properties compared to pure drug.
Anti-inflammatory studies were conducted in Wistar strain male albino rats and naproxen agglomerates
showed more significant activity than the pure drug.
Uniterms: Naproxen/micromeritic properties. Naproxen/spherical agglomerates/dissolution. Residual
solvents. Ulcerogenic potential. Bridging liquid.
Naproxeno, frmaco anti-inflamatrio, apresenta baixa solubilidade em gua, o que limita os efeitos
farmacolgicos. O presente trabalho foi realizado para estudar o efeito da aglomerao nas propriedades
micromerticas e na dissoluo. Aglomerados de naproxeno foram preparados por meio da utilizao
de sistema de trs solventes composto de acetona (bom solvente), gua (no-solvente) e diclorometano
(lquido de ligao). A DSC no resulta mostrou nenhuma mudana na droga depois de processo de
cristalizao. Estudos de difrao de Raios X do P (XRPD) mostraram picos agudos nos difratogramas
de aglomerados esfricos, com reduo mnima dea altura dos picos. Os solventes residuais esto
amplamente abaixo dos limites tolerados nos aglomerados. Os estudos de Microscopia Eletrnica de
Varredura (SEM) mostraram que esses aglomerados eram de estrutura esfrica e formados por grupos
de pequenos cristais. Os aglomerados apresentaram solubilidade, taxa de dissoluo e propriedades
micromerticas aprimoradas em comparao com o frmaco puro. Estudos anti-inflamatrios foram
conduzidos em ratos Wistar albinos masculinos e os aglomerados de naproxeno mostraram atividade
mais significativa do que o frmaco puro.
Unitermos: Naproxeno/propriedades micromerticas. Naproxeno/aglomerados esfricos/dissoluo.
Solventes residuais. Potencial ulcerognico. Lquido de ligao.

*Correspondence: D. Saritha. Department of Pharmaceutics, Sultan-ul-uloom

College of Pharmacy, Road No: 3, Banjara Hills, Hyderabad, Andhra Pradesh,
India. E-mail: daminenisaritha@yahoo.co.in

Article

Brazilian Journal of
Pharmaceutical Sciences
vol. 48, n. 4, oct./dec., 2012

668

INTRODUCTION
Recently the direct tablet compression method is
frequently and preferably used for tablet manufacturing,
since many processing steps (granulation, drying etc) are
eliminated and in addition wet technology can not be used
to moisture sensitivity agents (effervescent tablets) (Maghsoodi et al., 2007). In the direct tabletting method, it is
necessary to increase the flowability and compressibility of
the bulk powder in order to retain a steady supply of powder
mixture to the tabletting machine and sufficient mechanical
strength of the compacted tablet. In addition to increasing
the efficiency of the manufacturing process it is also important to increase bioavailability of the drug by improving the
solubility of the bulk drug powder. Spherical agglomeration
is a novel method to increase the bioavailability of the drug
that inherently has poor aqueous solubility. It is a multiple
unit process in which crystallization, agglomeration and
spheronization can be carried out simultaneously in one step
(Kulkarni et al., 2002). The resultant crystals have characteristic shape which dramatically improved the micromeritic
properties such as flowability, packability and compressibility so that direct tabletting or coating is possible without
further processing (mixing, agglomeration, sieving).
Spherical agglomeration is a process of formation
of aggregates of crystals held together by liquid bridges.
The agglomerates are formed by agitating the crystals in a
liquid suspension in presence of binding agent. The bridging liquid should be immiscible in the suspending medium,
but capable of cementing the particles to be agglomerated.
This technique can also be exploited to increase solubility,
dissolution and hence bioavailability of poorly soluble
drugs (Di Martino, 1999; Sano, 1987; Kawashima et al.,
1990). These modifications allow for the practice of more
efficient manufacturing methods that could save time and
reduces economic risk.
Naproxen is an anti-inflammatory drug which exhibits poor water solubility and unsuitable for direct tabletting due to its poorly compressible properties, although
strongly demanded in commercial production by direct
tabletting. It exhibits poor flow, and a high tendency of
adhesion. To improve the micromeritic properties, dissolution rate and bioavailability, spherical crystallization
method is attempted.

MATERIAL AND METHODS

Naproxen was kindly provided by Divis labs, Hyderabad, India. Acetone and dichloromethane were purchased
from Merck, Mumbai, India. All chemicals and buffers
used were of analytical grade.

D. Saritha, P. S. C. Bose, P. S. Reddy, G. Madhuri, R. Nagaraju

Selection of solvent proportions for spherical

agglomeration

Ternary phase diagram of acetone, dichloromethane

and water was constructed to select a suitable zone with
appropriate ratio of three solvents for the preparation of
spherical agglomerates.
Preparation of spherical agglomerates of
naproxen

For spherical agglomeration of naproxen acetone

was found to be suitable solvent due to its excellent solubility and miscibility with dispersing water phase (poor
solvent). Dichloromethane was chosen as bridging liquids
because of its good wettability with the drug. Naproxen
5 g was dissolved in 25 mL of acetone at 45 C until a
clear solution was obtained. Drug solution was poured
quickly in to 62.5 mL of water maintained at 20 C, under
continuous stirring at 500 rpm with a propeller type agitator. When fine crystals of naproxen begin to precipitate (5
min), 12.5 mL of dichloromethane was added slowly drop
wise, followed by 30 min stirring. Agglomerates obtained
were separated from the solution by filtration and dried at
60 C for 6 hours in an oven. The dried agglomerates were
then stored in screw-capped jar in a desiccator.
Drug content

Spherical agglomerates (50 mg) were triturated with

10 mL of water. Allowed to stand for 10 min with occasional swirling and methanol was added to produce 100
ml. 5 ml of this solution was mixed with equal volumes
of methanol and phosphate buffer pH 7.4 to produce 100
mL. Absorbance of the resulting solution was measured
at 234 nm [6].
Melting point

Melting point of naproxen crystals was determined

by placing the drug filled capillary tubes in digital melting
point apparatus (Polmon, Hyderabad, India). Melting point
was noted and compared with the pure drug.
Differential Scanning Calorimetry (DSC)

To detect possible polymorphic transition during

the agglomeration process, DSC studies were carried
out by using differential scanning calorimeter (DSC 60,
Shimadzu, Japan) with DuPont 9900 thermal analyzer. All
accurately weighed samples (about 1 mg of naproxen or its

Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization

equivalent) were placed in sealed aluminum pans, before

heating under nitrogen flow (20 mL/min) at a scanning rate
of 10 C min-1, from 25 C to 250 C. An empty aluminum
pan was used as reference.
X-ray analysis

X-Ray powder diffraction patterns were used to

detect possible polymorphic transition during the crystallization process. X-Ray powder diffraction patterns were
obtained at room temperature using X Pert MPD diffractometer (Philips, Holland), with Cu as anode material and
graphite monochromator, operated at a voltage of 40mA,
45 kV. The samples were analyzed in the 2q angle range
of 3-50 and the process parameters used were set as scan
step size of 0.0170 (2q), scan step time of 51.0362 sec and
time of acquisition of 1 h. 2q values were processed using
multidimensional minimization programme to calculate
cell volume, cell parameters and space grouping.
Scanning electron microscopy

The Scanning electron microscopic (Joel- LV-5600,

USA, with magnification of 250 X) photographs were
obtained to identify and confirm spherical nature and
morphological characters of the agglomerates.
Surface topography

Tracings of spherical agglomerates were taken using

Camera Lucida fixed to optical microscope (magnification
45 X) (Paradkar et al., 2002) and were used to calculate
circulatory factor (S) as S=P2/ (12.56XA), where A is area
(cm2) and P is perimeter (cm).
Micromeritic properties

Particle size of pure drug was determined by microscopic method using calibrated ocular micrometer and
size of spherical agglomerates was determined by sieving
method [8]. Apparent particle densities of agglomerated
and pure drug were measured using a Pycnometer (Gay
Lussac, India). Carrs index was determined from powder volumes at the initial stage and after 1250 tappings
to constant volume (Electrolab, Mumbai). The angle of
repose of agglomerated and pure drug was measured by
fixed funnel method.
Crushing strength

Crushing strength of agglomerates was determined

669

using modified Jarosz and Parrots mercury load cell

method (Paradkar et al., 2002). It was carried out using a
10 mL glass hypodermic syringe. The modifications include removal of the tip of the syringe and the top end of
the plunger. The barrel was used as a hollow support and
guide tube with close fitting to the plunger. A window was
cut at the lower end of the barrel to facilitate placement
of the agglomerate on the base platen. The plunger acted
as a movable platen. It was set directly on the agglomerate, positioned on the lower platen. Mercury was added
to the plunger at a rate of 10g/sec from a separating funnel, from a fixed height. The total weight of mercury plus
that of plunger required to break the agglomerate was the
crushing strength (g).
Determination of residual solvents concentration

Residual water in spherical agglomerates was determined using Karl Fischer (Polmon, Hyderabad, India)
titrimeter, calibrated with sodium tartrate. Gas chromatography (Shimadzu GC-14B chromatograph, Japan) was
used to estimate residual Acetone and dichloromethane in
spherical agglomerates (Piera Di Martino et al., 2000).
Solubility studies

The solubility of naproxen spherical agglomerates in

water was determined by taking excess quantity of spherical agglomerates into screw- capped 50 mL glass vials.
The vials were shaken for two hours on mechanical shaker
(Nocent et al., 2001). The solution was filtered and analysed for drug content spectrophotometrically at 234 nm.
Dissolution studies of agglomerates

The dissolution of naproxen pure drug and spherical

agglomerates sample was determined by using USP dissolution apparatus XXIV-Type II (Electro Lab, Mumbai,
India). The dissolution medium used was 900 ml of phosphate buffer (pH 7.4).
The 5 mL of sample solutions were withdrawn at
predetermined time intervals and then filtered. A volume of
5 mL of phosphate buffer (pH 7.4) was replaced in the dissolution flask to maintain volume constant. The amount of
dissolved naproxen in the sample solutions was analyzed
spectrophotometrically at 234 nm.
In vivo evaluation of agglomerates

The naproxen agglomerates obtained were subjected

to in vivo studies to assess their anti-inflammatory activity

670

and to screen for ulcerogenic potential, the major adverse

effect caused by the naproxen.
Evaluation of anti-inflammatory activity

The anti-inflammatory activity of prepared naproxen

agglomerates was evaluated by the carrageenan-induced
rat hind paw edema method (Rao et al., 1994). The experimental protocol was designed and approval of Institutional
Animal Ethics Committee (IAEC) (Reg. No. 557/02/c/
CPCSEA) was obtained. Wistar strain male albino rats
weighing between (150-200 g) were used. The animals
were in a light controlled 12 hours cycle with free access
to food and water. Animals were fasted overnight before
experiment with free access to water (Lichtenberger et
al., 2009). Anti-inflammatory activity of the naproxen agglomerates was compared to the pure naproxen drug. Animals were divided into three groups of six animals each.
Group I (control I) received water. Group II, (standard) received 25 mg/kg pure naproxen and Group III received 25
mg/kg naproxen agglomerates. After one hour, paw edema
was induced by injecting 50 L of 1% w/v carrageenan
into the sub planar region of the left hind paw. Paw volume
was determined after five hour in all groups. Difference
in the paw volume, determined before and after injection
of the edema-provoking agent indicated the severity of
edema. One control group and reference group were used
in this study. Volumes of right hind paw of controls and
treated animals were measured with a plethysmometer and
the percentage inhibition of inflammatory reaction was
determined for each animal by comparison with control
and calculated by the following formula.

where, V control = mean edema of rats in control group; V test

= mean edema volume of rats in tested group
Assessment of ulcerogenic potential of naproxen
agglomerates

Healthy Wistar strain male albino rats weighing between 150 200 g were used for the study and individually
maintained under standard conditions (12 h light and dark
cycles, 25 22 oC and 3560% humidity). The rats were
fed with animal fed pellets and had free access to water.
The rats were divided into three groups each containing 6 animals that are controlled (group-1), standard
(group-2) and test group (group-3). Animals were kept
under fasting with free access to water for 48 h before

D. Saritha, P. S. C. Bose, P. S. Reddy, G. Madhuri, R. Nagaraju

test. Group 1 received plain water, Group 2 received pure

naproxen (25 mg/kg) and Group 3 received naproxen
agglomerates (25 mg/kg) and was sacrificed after 6 h
(Veerapur et al., 2004). Their stomachs were isolated
and opened along the greater curvature, the mucosa was
washed under slow running tap water and the number and
size of ulceration was scored as per the method (Rao et al.,
1994). The contents were centrifuged at 3000 rpm for 10
min. Total acidity and pH was analyzed from the decanted
supernatant by using broad range pH paper.
Ulcer index

The washed stomach was fixed on a cork plate and

the number and severity of the ulcers were measured using
the scores (Kulkarni, 2002).
Severity Score:
0 = Normal colored stomach
0.5 = Red coloration
1 = Spot ulcer
1.5 = Hemorrhagic streaks
2 = Ulcers 3 but 5
3 = Ulcers > 5.

RESULTS AND DISCUSSION

Selection of solvent proportions for spherical
agglomeration

Spherical agglomerates of naproxen were prepared

by simple agglomeration technique using a three solvent
system. It involves a good solvent, a poor solvent and
bridging liquid. Selection of these solvents depends on
miscibility of the solvents and the solubility of the drug
in individual solvents. Accordingly different combinations were tried by ternary phase diagram to produce
optimum solvent system (Di Martino et al., 2000). The
drug solubility and mutual miscibility of solvent systems
are examined. Acetone, water and dichloromethane were
selected as solvent system.
Acetone is miscible with water and dichloromethane. The ternary diagram is envisaged, to select the solvent
composition. The points on the vertex correspond to a pure
liquid; those on the sides correspond to a mixture of only
two liquids. Since the presence of three liquids is necessary (good solvent, bridging solvent and poor solvent)
for spherical agglomeration, points on the sides of the
triangle are excluded. 36 points remain for experiment.
Each triangle in the ternary diagram was investigated for
the agglomeration. The optimal ratio for spherical agglomeration was selected as 25:62.5:12.5.

Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization

Preparation of spherical agglomerates of

naproxen

The proportions of acetone/water/dichloromethane

were chosen for the study is 25/62.5/12.5 mL respectively.
Agglomerates were formed by agitating the crystals in a
liquid suspension and adding a bridging liquid, which preferentially wets the crystal surface to cause binding. The
addition of bridging liquid (dichloromethane) promotes
the formation of liquid bridges between the drug crystals
to form agglomerates.
To optimize naproxen spherical agglomeration by
acetone/water/dichloromethane system, other process
parameters were considered such as amount and mode
of addition of bridging liquid, stirring speed and time,
temperature.
The average diameter of agglomerates was found to
increase with increasing amount of dichloromethane in the
agglomeration medium due to excessive bridging liquid
on the surface for coalescence.
Size of agglomerates is very much dependent on
the degree of agitation. Due to agitation droplets will
be formed in the agglomeration medium and it induces
movement of droplets from in to out. The intensity
of this internal circulation depends on the speed. At
lower stirring rate (<400 r/min) reduces the possibility
of obtaining agglomerates due to slow circulation of the
droplets in the medium and slight collision between the
droplets. At optimum speed (500 r/min) more compact
and dense agglomerates were obtained. Higher speed
(>600 r/min) induces agglomerate destruction due to more
impact energy for collision due to increased turbulence
resulting in formation of agglomerates with irregular
shape.
The temperature of solvent system was found to
have pronounced effect on the process of agglomeration.
Agglomeration was not observed when the process was
carried out at 103 oC. It could be due to reduced solubility
of drug in the solvent system. When the temperature was
increased to 453 oC very large agglomerates were produced due to enhanced solubility (Saturation of the drug
in the medium). Optimum agglomeration was achieved at
203 oC due to optimum solubility of the drug.
Addition of bridging liquid plays vital role in formation off agglomerates. When the bridging liquid was added
at a time agglomerates were of irregular geometry which
may be due to its localization and hence its unavailability for efficient agglomeration. Drop wise addition with
continuous agitation resulted in agglomerates of regular
geometry which can be attributed to uniform distribution
of bridging liquid.

671

Drug content

The drug content obtained was in the range of

99.121.54%.
Melting point

The melting point of naproxen pure drug and agglomerates was found to be in the range 150 C -155 C
and was observed that there was no change in melting
points of pure drug and agglomerates. Thus, formation
of polymorphs was over ruled, as crystal habit will not
change the melting point.
Differential scanning calorimetry (DSC)

DSC thermograms of pure and naproxen agglomerates are illustrated in Figure 1. The DSC pattern of pure
naproxen and agglomerates showed a sharp endothermic
peak at 153 C corresponding to its melting point. Sharp
melting point with flat base line, which indicated that the
material was not affected by hydration, solvation, polymorphic transition and in addition there was no interaction
of drug with solvents.
X-ray analysis

X-Ray powder diffraction (XRD) is a powerful

technique for the identification of crystalline solid phase.
Every crystalline solid phase has a unique XRD pattern,
which can form the basis for its identification. XRD pattern
in 2 range showed the diffraction peaks, characteristic
of naproxen in both pure and agglomerate forms Figure
2, suggesting that crystallization did not cause any structural modifications. The slight differences in the relative
intensities of their peaks at the respective 2 values may be
attributed to differences in the particle size or crystallinity
of the sample. The disappearance of peaks in naproxen
agglomerates at 32 and 46 was due to the markedly
different crystal habits. Therefore the relative abundance
of the planes exposed to the X-ray source would have been
altered, producing the disappearance of peaks or variations
in the relative intensities of the peak.
XPRD spectral data of pure naproxen and spherical agglomerates were showed similar peaks indicating
that there was no structural alteration occurred due to the
technique employed for preparing spherical agglomerates.
Scanning electron microscopy

The surface morphology and shape of the agglomer-

672

D. Saritha, P. S. C. Bose, P. S. Reddy, G. Madhuri, R. Nagaraju

A naproxen pure drug, B naproxen agglomerates

FIGURE 1 - Differential scanning calorimetric thermograms of naproxen and agglomerates DSC chromatogram clearly shows that
pure drug (A) and spherical agglomerate obtained (B) showed melting range of 148-158 C indicating that there was no chemical
modification in the drug due to the method employed.

ates were identified in scanning electron microscopy. The

pure naproxen was in the form of plate like particles as
appeared in Figure 4. Where as naproxen agglomerates
prepared were having clusters of plate shaped particles,
which are not that spherical but irregular in shape as shown
in Figure 3. Upon high magnification it was further observed that surfaces are not smooth and no liquid bridges
found in between particles shown in Figure 4. Thus the
produced clusters may not be spherical agglomerates, but
bunches of plate like crystals. This cluster formation may
be responsible for enhancement of flow property, packability and drug release rate as observed in our investigation.
Surface topography

Agglomerates obtained were moderately spherical in

shape with circularity factor ranging between 0.891 - 0.912
(1 Indicates the spherical shape).
Micromeritic properties

The micromeritic properties like bulk density, tapped

density, angle of repose and Carrs index were determined

and shown in Table I. The bulk and tapped densities of the
spherical agglomerates were lower than the corresponding
value of the pure sample, with the particle size and sphericity being higher. The lower density is likely to be related
to the intraparticle porosity and reduced bulk density of
the treated samples indicates a greater porosity within the
agglomerated particles. Carrs index for agglomerates was
found to be lower when compared to pure drug. This may
be due to the formation of agglomerates. Fine particles
having high surface to mass ratios are more cohesive than
coarser particles, hence more influenced by gravitational
force. Decreased values of Carrs index for agglomerates
indicate better packability, and that they might be suitable
for direct tabletting. Flow properties of the agglomerates
were reflected by angle of repose. It was found that angle
of repose of agglomerates were decreased when compared
to pure naproxen. Such decreased value indicates improvement in flowability.
Lower densities of spherical agglomerates than
the pure sample indicate better spherecity and porosity.
Lower Carrs index for agglomerates makes their pack-

Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization

673

FIGURE 2 - X-Ray diffraction spectra of naproxen and agglomerates

FIGURE 3 - SEM of A: naproxen pure drug, B: agglomerate, C: surface of the agglomerate. The powder was irregularly shaped

(A) and spherical agglomerates were obtained after the successful completion of experiment (B). The surface of the spherical
agglomerate (C) shows that the minute particles of the drug have agglomerated to give a spherical shape.

674

D. Saritha, P. S. C. Bose, P. S. Reddy, G. Madhuri, R. Nagaraju

TABLE I- Micromeritic properties of naproxen pure drug and

agglomerates
Properties

Particle size (mm)

Pure Drug
5-10

Flow rate (g/s)

5.42 1.87
Angle of repose
54 1.35
Tapped density (g/mL)
0.211 0.24
Bulk density (g/mL)
0.134 0.128
Carrs index
36.492
Mechanical strength ( % )
Values are average of 3 determinations (n = 3)

Agglomerates
830 (Average
particle size)
11.23 0.93
46 0.79
0.349 0.14
0.237 0.43
32.09
0.974 1.37

ability better, and might be suitable for direct tabletting.

Flow properties of the agglomerates were reflected by
angle of repose, and a lower value shows improvement
in flowability.
Crushing strength

The crushing strength of agglomerates was in the

range of 105-110 g and was unaffected by the process
variables.
Residual solvents concentration

The results of residual solvent concentration in

naproxen agglomerates reported in Table II. According
to Guideline for residual solvents Q3C (International
Conference on Harmonization of Technical Requirements
For Registration of Pharmaceuticals For Human Use),
acetone and dichloromethane are class 3 class 2 solvents
respectively (solvents with low toxic potential and solvents should be limited), thus the limits of 5000 ppm and
600 ppm are acceptable without justification. The results
obtained for acetone and dichloromethane are largely
below the tolerated limits.
TABLE II- Residual solvent contents of naproxen agglomerates

Residual solvent

Concentration
(ppm)
0.912 0.23%
4.2036 1.458
3.561 2.14

Concentration limit
(ppm)*
5000
600

Water
Acetone (Class III)
Dichloromethane
(Class II)
*As per ICH guide lines. Values are average of 3 determinations
(n = 3)

The residual solvent concentration of acetone and

dichloromethane (solvents with low toxic potential and
solvents should be limited), obtained were largely below
the tolerated limits according to ICH guidelines and thus
the agglomerates are acceptable
Solubility studies

Spherical agglomerates showed distinct solubility

pattern in water and buffer (pH 7.4 phosphate). It was
noted that solubility of spherical agglomerates increased
when compared with pure drug as shown in Table III. But,
it was found that the solubility of naproxen was more in
buffer than water which can be owed to its poor water
solubility in lower pH.
TABLE III- Solubility Data of naproxen
Solubility medium
Pure Drug
Agglomerates
Water (% W/V)
0.00586 1.031
0.01795 0.93
7.4 Phosphate buffer
3.94 0.18
7.71 0.34
(% W/V)
Values are mean standard deviation (n = 3).

Spherical agglomerates showed increased solubility

in water and buffer (pH 7.4 phosphate) compared to pure
drug. But, it was found that the solubility of naproxen was
more in buffer than water which can be owed to its poor
water solubility in lower pH.
Dissolution studies of agglomerates

The dissolution rate of pure naproxen is less than

that of naproxen agglomerates. The reason for faster dissolution is good wettability of the agglomerates. After
applying one way analysis of variance (ANOVA) it has
been observed that there was significant difference (p <
0.05) between the dissolution profiles of agglomerates
when compared to pure sample.
In vivo evaluation of agglomerates

Anti-inflammatory activity and ulcerogenic potential were carried out for pure naproxen and agglomerates.
Table IV shows the results of paw edema and percentage
inhibition of carrageenan-induced paw edema in rats
treated with pure naproxen and naproxen agglomerates. An
extremely significant (p<0.001) inhibition of carrageenan
induced paw edema was observed in animals treated with
naproxen agglomerates in comparison with control during
the entire 3 h duration of the study, significant (p<0.05) in-

Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization

675

TABLE IV- Anti-inflammatory activity of pure naproxen and naproxen agglomerates

Group
Treatment
Control
Water
Standard
25 mg/kg pure naproxen
Test
25 mg/kg naproxen agglomerates
Values are mean standard deviation (n = 3).

Time (h)
5
5
5

hibition of carrageenan induced paw edema was observed

in animals treated with naproxen agglomerates in comparison with naproxen pure drug during the entire 5 h duration
of the study. This may be due to increased dissolution of
agglomerates over pure drug, leading to better absorption
and onset of action of drug. There was no drastic change
in gastric pH when treated with naproxen and naproxen
agglomerates. No ulcers were observed and the colour of
stomach was normal.
Paw edema and percentage inhibition of carrageenan-induced paw edema in rats show a significant inhibition
(p<0.05) in animals treated with naproxen agglomerates
due to increased dissolution of agglomerates over pure
drug, leading to better absorption and onset of action of
drug. Hence, agglomerates showed better anti-inflammatory activity over the pure drug.
Therefore, the results of the in vivo studies clearly
demonstrate that the naproxen agglomerates showed better anti-inflammatory activity over the pure drug, thus
confirming the better therapeutic efficacy of the naproxen
agglomerates.

CONCLUSION
Naproxen agglomerates that were prepared by simple
spherical crystallization technique exhibited improved micromeritic properties and dissolution rate. DSC and XRD
study showed that there is no change in the crystal structure
and polymorphism was not occurred. Due to the significant
improvement of micromeritic properties, this technique
may be used for formulation of naproxen tablets by direct
compression method. The agglomerates were found to be
having better anti-inflammatory activity in the rats when
compared to pure drug due to improved solubility.

Paw volume mean

0.46
0.281.36
0.162.57

% Inhibition
--39.132.16
65.212.85

REFERENCES
AULTON, M. E.. Aultons Pharmaceutics the design and
manufacture of medicine. 3.ed. London: Churchill
Livingstone Elsevier, 2007. p.355-357.
DI MARTINO, P.; BARTHELEMY, C.; PIVA, F.; JOIRIS, E.;
PALMIERI,G.F.; MARTELLI, S. Improved dissolution
behavior of fenbufen by spherical crystallization. Drug Dev.
Ind. Pharm., v.25, n.10, p.1073-1081, 1999.
DI MARTINO, P.; DI CRISTOFARO, R.; BARTHELEMY,
C.; JOIRIS, E.; PALMIERI FILIPPO, G.; SANTE, M.
Improved compression properties of propyphenazone
spherical crystals. Int. J. Pharm., v.197, n.1-2, p.95-106,
2000.
INDIAN PHARMACOPOEIA. The Indian Pharmacopoeia
commission. 6.ed. PA: Ghaziabad, 2010. v.3, p.1754-1758.
KULKARNI, P.K.; NAGAVI, B.G. Spherical crystallization.
Ind. J. Pharm. Educ., v.36, n.5, p.66-73, 2002.
KULKARNI, S.K. Hand book of experimental pharmacology.
3.ed. New Delhi: Vallabh Prakashan, 2002. 149 p.
LICHTENBERGER, M.; ROMERO, J.J.; DIAL, E.J.; MOORE,
J.E. Naproxen-PC: A GI safe and highly effective antiinflammatory. Inflammopharmacology, v.17, n.1, p.1-5,
2009.

ACKNOWLEDGEMENTS

MAGHSOODI, M.; HASSAN-ZADEH, D.; BAZEGARJALALI, M. Improved compaction and packing properties
of naproxen agglomerated crystals obtained by spherical
crystallization technique. Drug Dev. Ind. Pharm., v.33, n.1,
p.1216-1224, 2007.

The authors are thankful to M/S Divis Labs, Hyderabad, India for the gift sample of Naproxen. We also
thank the Quality Assurance Deputy Manager, Macleods
Pharmaceuticals, Vapi, Gujarat for gas chromatographic
analysis.

NOCENT, M.; BERTOCCHI, L.; ESPITALIER, F.; BARON,

M.; COURRAZE, G. Definition of a solvent system for
spherical crystallization of salbutamol sulfate by quasiemulsion solvent diffusion (QESD) method. J. Pharm. Sci.,
v.90, n.10, p.1620-1627, 2001.

676

PARADKAR, A.R.; PAWAR, A.P.; CHORDIYA, J.K.; PATIL,

V.B.; KETKAR, A.R. Spherical crystallization of celecoxib.
Drug Dev. Ind. Pharm, v.28, n.10, p.1213-1220, 2002.
RAO, C.M.; RAMESH, K.V.; BIARY, K.L.; KULKARNI,
D.R. Zinc complexes of NSAIDS abolish gastric ulceration
propensity of parent drugs. Indian Drugs, v.28, n.2, p.6467, 1990.
SANO, A.; KURIKI, T.; HANDA, T.; TAKEUCHI, H.;
KAWASHIMA, Y. Particle design of tolbutamide in the
presence of soluble polymer or surfactant by spherical
crystallization technique: improvement of dissolution rate.
J. Pharm. Sci., v.76, n.6, p.471-474, 1999.

D. Saritha, P. S. C. Bose, P. S. Reddy, G. Madhuri, R. Nagaraju

SANO, A.; KURIKI, T.; KAWASHIMA, Y.; TAKEUCHI, H.;

NIWA, T.; HINO, T. Particle design of tolbutamide by
the spherical crystallization technique. III. Micromeritic
properties and dissolution rate of tolbutamide spherical
agglomerates prepared by the quasi-emulsion solvent
diffusion method and the solvent change method. Chem.
Pharm. Bull., v.38, n.3, p.733-739, 1990.
VEERAPUR, V.P.; BADIGER, A.M.; JOSHI, S.D.; NAYAK,
V.P.; SHASTRY, C.S. Antiulcerogenic activity of various
extracts of dodonaea viscosa (L) Jacq.Leaves. Ind. J.
Pharm. Sci., v.66, n.4, p.407-411, 2004.
Received for publication on 17th September 2011
Accepted for publication on 23th July 2012